GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » EXMceuticals Inc (STU:9OM1) » Definitions » Earnings per Share (Diluted)

EXMceuticals (STU:9OM1) Earnings per Share (Diluted) : €-0.12 (TTM As of Mar. 2021)


View and export this data going back to 2019. Start your Free Trial

What is EXMceuticals Earnings per Share (Diluted)?

EXMceuticals's Earnings per Share (Diluted) for the three months ended in Mar. 2021 was €-0.02. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2021 was €-0.12.

EXMceuticals's EPS (Basic) for the three months ended in Mar. 2021 was €-0.02. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2021 was €-0.12.

EXMceuticals's EPS without NRI for the three months ended in Mar. 2021 was €-0.02. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2021 was €-0.10.


EXMceuticals Earnings per Share (Diluted) Historical Data

The historical data trend for EXMceuticals's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EXMceuticals Earnings per Share (Diluted) Chart

EXMceuticals Annual Data
Trend Jun11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.03 -0.01 -0.01 -0.29 -0.16

EXMceuticals Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 -0.07 -0.02 -0.01 -0.02

Competitive Comparison of EXMceuticals's Earnings per Share (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, EXMceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EXMceuticals's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, EXMceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where EXMceuticals's PE Ratio falls into.



EXMceuticals Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

EXMceuticals's Earnings Per Share (Diluted) for the fiscal year that ended in Jun. 2020 is calculated as

Diluted Earnings Per Share (A: Jun. 2020 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-6.063-0)/39.578
=-0.15

EXMceuticals's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2021 is calculated as

Diluted Earnings Per Share (Q: Mar. 2021 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-1.626-0)/74.690
=-0.02

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


EXMceuticals  (STU:9OM1) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


EXMceuticals Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of EXMceuticals's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


EXMceuticals (STU:9OM1) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
421 7th Avenue S.W., 30th Floor, Calgary, AB, CAN, T2P 4K9
EXMceuticals Inc is a bio-science company that believes in the potential health and wellness benefits of hemp and cannabis. EXM is an emerging player in the market, with ambition and potential to become the suppliers of highest-grade cannabis ingredients. It is creating an industrial-scale, GMP, Pharmaceutical Grade Extraction and Refining facility inside the European Union, near Lisbon Portugal. It has an existing and licensed cannabis R&D facility and pilot refinery in Lisbon Portugal. EXM is targeting the B2B marketplace and will supply pure ingredients and API's to the pharmaceutical, medicinal and wellness industry.

EXMceuticals (STU:9OM1) Headlines

No Headlines